538 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
All the 2020 Pre-JPM News Healthcare Investors Need to Know https://www.fool.com/investing/2020/01/11/all-the-2020-pre-jpm-news-healthcare-investors-nee.aspx?source=iedfolrf0000001 Jan 11, 2020 - The Super Bowl of healthcare kicked off early for these companies.
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020 http://www.zacks.com/stock/news/707821/3-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2020?cid=CS-ZC-FT-analyst_blog|industry_focus-707821 Jan 08, 2020 - Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
Top Stock Reports for JPMorgan, Sanofi & General Electric http://www.zacks.com/research-daily/706515/top-stock-reports-for-jpmorgan-sanofi-general-electric?cid=CS-ZC-FT-research_daily-706515 Jan 07, 2020 - Top Stock Reports for JPMorgan, Sanofi & General Electric
Amicus Progresses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/700524/amicus-progresses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-700524 Jan 03, 2020 - Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning https://www.fool.com/investing/2019/12/14/sanofi-says-its-25-billion-biotech-takeover-is-jus.aspx?source=iedfolrf0000001 Dec 14, 2019 - Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|stock_roundup-668756 Dec 13, 2019 - This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America http://www.zacks.com/stock/news/667191/the-zacks-analyst-blog-highlights-novartis-abbvie-sanofi-pioneer-natural-resources-and-aqua-america?cid=CS-ZC-FT-press_releases-667191 Dec 12, 2019 - The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
Top Research Reports for Novartis, AbbVie & Sanofi http://www.zacks.com/research-daily/665423/top-research-reports-for-novartis-abbvie-sanofi?cid=CS-ZC-FT-research_daily-665423 Dec 11, 2019 - Top Research Reports for Novartis, AbbVie & Sanofi
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent http://www.zacks.com/stock/news/665440/sanofi-regeneron-to-amend-agreement-for-kevzara-praulent?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-665440 Dec 11, 2019 - Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session http://www.zacks.com/stock/news/665353/sanofi-sny-looks-good-stock-adds-62-in-session?cid=CS-ZC-FT-tale_of_the_tape|price_movement-665353 Dec 11, 2019 - Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Pages: 123456789...54

<<<Page 4>